Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Fluorescent Skin Dye Offers Temporary Option for Skin Cancer Management

XTALKS VITALS NEWS

A team of researchers at the University of California, Los Angeles, have developed a novel fluorescent ink to temporarily tag the skin cancer lesion.

Share this!

January 4, 2017 | by Sarah Hand, M.Sc.

With the exception of melanoma, most types are skin cancer lesions are identified and tagged using small tattoos. While this method helps physicians track which areas need additional treatment, the long-lasting tattoo ink used can cause inflammation and can even be confused with lesions when a patient is being monitored in the future.

A team of researchers at the University of California, Los Angeles, have developed a novel fluorescent ink to temporarily tag the skin cancer lesion. Not visible by the naked eye, the dye only fluoresces under light with a wavelength of 465 nanometers.

“Tattooing has been utilized by the medical community for precisely demarcating anatomic landmarks,” said the study authors in their ACS Nano publication. “This practice is especially important for identifying biopsy sites of nonmelanoma skin cancer due to the long interval (i.e., up to 3 months) between the initial diagnostic biopsy and surgical treatment.”



Unlike the standard tattoo dye, the fluorescent ink fades over time. The researchers reported that the retention time of the dye was around 3 months, which coincides with the average time between a patient’s initial biopsy and when they receive surgical treatment.

The transdermal dye is composed of cross-linked fluorescent supramolecular nanoparticles and a fluorescent conjugated polymer center. The fluorescent dye has only been tested in mice, where it showed no propensity to trigger local inflammation.

According to the Canadian Cancer Society, nonmelanoma skin cancer is the most common form of the disease diagnosed in Canada. Statistics on the incidence of these types of skin cancer are, however, difficult to collect because diagnosis and treatment are often both done by a patient’s regular physician.


Keywords: Skin Cancer, Biopsy, Surgery


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News


Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News


Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

One Patient’s Perspective on Clinical Trials

REGISTER FOR THESE WEBINARS

Planning and Conducting Trials of the Latest Immunotherapies


ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation


Medical Devices: Reviewing Regulatory Changes in the US and EU


Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.